Home » Posts tagged 'exercise of warrants' (Page 2)
Tag Archives: exercise of warrants
Ananda Developments #ANA – Exercise of Warrants
Ananda announces that 16,863 ordinary shares of 0.2p each in the Company (“Ordinary Shares”) have been issued following the exercise of warrants at 0.45p per share.
Application will be made for the new Ordinary Shares to be admitted to trading on the Access segment of the AQSE Growth Market and admission is expected to become effective on Tuesday, 11 January 2022.
Following this issue, the Company has 797,579,590 Ordinary Shares in issue, each share carrying the right to one vote.
This figure of 797,579,590 Ordinary Shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.
Advanced Oncotherapy (AVO) – Exercise of Warrants and issue of Shares
Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has today issued 14,000 new ordinary shares of 1p in the Company at a price of 6 pence per New Share pursuant to the exercise of 14,000 warrants.
Application has been made for the 14,000 Shares to be admitted to trading on AIM and it is expected that Admission will occur on or about 21 April 2016. The Shares will rank pari passu in all aspects with the existing ordinary shares of the Company.
Total voting rights
Following Admission, the Company’s enlarged issued share capital will comprise 1,418,342,375 ordinary shares, with voting rights. The Company does not hold any ordinary shares in treasury. Therefore the total number of ordinary shares in the Company with voting rights will be 1,418,342,375. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA’s Disclosure and Transparency Rules.
For further information, please contact:
Advanced Oncotherapy Plc |
|
Michael Sinclair, Chief Executive Officer |
Tel: +44 20 3617 8728 |
Nicolas Serandour, Chief Operating and Financial Officer |
|
|
|
Stockdale Securities (Nomad & Joint Broker) |
|
Antonio Bossi / David Coaten |
Tel: +44 20 7601 6100 |
|
|
Beaufort Securities (Joint Broker) |
|
Jon Belliss / Elliot Hance |
Tel: +44 20 7382 8300 |
|
|
Walbrook PR (Financial PR & IR) |
Tel: +44 20 7933 8780 or avo@walbrookpr.com |
Paul McManus / Anna Dunphy |
Mob: +44 7980 541 893 / Mob: +44 7876 741 001 |